AbbVie vs. Eli Lilly: Which Drug Stock Wins in 2026?
Two pharma giants, one portfolio slot. Here's how AbbVie and Eli Lilly stack up for 2026.
If you're deciding between AbbVie and Eli Lilly for your 2026 portfolio, you're not alone. These two healthcare heavyweights consistently top watchlists, and for good reason — both carry blockbuster drugs, loyal investor bases, and the kind of revenue visibility that growth traders crave.
AbbVie built its empire on Humira, and while biosimilar competition has chipped away at that dominance, the company has fought back with Skyrizi and Rinvoq stepping up as next-generation revenue drivers. That transition story is still playing out, and how well it lands could define AbbVie's 2026 performance. The dividend is a major draw too — AbbVie is a Dividend King territory contender that income investors aren't going to walk away from easily.
Read more SpaceX Shares Hover Near $135 Offer Price: What Comes Next →
Eli Lilly, on the other hand, is riding one of the hottest waves in modern pharma. Its GLP-1 drugs — Mounjaro for diabetes and Zepbound for obesity — have turned Lilly into a market darling. The weight-loss drug boom isn't slowing down, and Lilly is positioned at the front of that queue. The catch? You're paying a premium valuation for that growth story, which means any pipeline stumble hits harder.
From a pure momentum angle, Lilly has the narrative. From a value-and-income angle, AbbVie makes the case. Your move depends entirely on whether you want to chase growth or collect yield while you wait. Neither pick is wrong — they just serve different strategies. Diversified investors might argue you don't have to choose at all.
Continue reading at Yahoo Finance.
